Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
miR-7a-5p and PARP1 in neonatal brain injury
2026-11-21
A literature-focused analysis of how the cited study links reduced miR-7a-5p to PARP1-dependent parthanatos in experimental hypoxic-ischemic encephalopathy, and why the findings remain mechanistic rather than clinical evidence.
How Andarine Readouts Fit Together
2026-11-20
Andarine and S-4 illustrate why receptor binding, AR-mediated transcription, and androgen-responsive tissue growth are related but non-equivalent measurements. Together, the documented findings support a constrained mechanism involving androgen receptor signaling, while leaving selectivity, translation across species, and clinical meaning unresolved.
How a Lysosomal pH Probe Reports Cellular Change
2026-11-20
CQ-Lyso is described as a lysosome-targeting chromoquinoline fluorescent probe for tracking dynamic lysosomal pH changes in living cells with single-wavelength excitation. Its documented role supports interpretation of fluorescence as a pH-sensitive cellular readout, but the available description does not establish quantitative calibration, specificity, or performance across biological models.
What p53 mRNA–LNP Evidence Shows
2026-11-19
Published evidence supports lipid nanoparticles as a plausible carrier class for nucleic-acid therapies, but p53 mRNA findings remain largely preclinical and formulation-specific. The most important interpretive question is whether observed tumor-cell effects reflect p53 pathway restoration, carrier biology, combination-drug activity, or some mixture of these mechanisms.
When Context Changes a Cancer Result
2026-11-19
A result in cancer biology derives its meaning from the model, perturbation, readout, and material context in which it was obtained. This editorial examines how a mouse mammary-tumor study connected CCR7 with Notch1 signaling while distinguishing mechanistic evidence from purification-material claims and clinical interpretation.
What Does Paxillin Detection Actually Measure?
2026-11-18
Paxillin detection can connect integrin–matrix engagement with focal-adhesion organization, but the biological meaning of a signal depends on whether the assay measures abundance, location, or biochemical association. This distinction is central to focal adhesion protein research and cytoskeletal protein analysis.
What Does EDANS Fluorescence Measure?
2026-11-18
EDANS fluorescence is not a single biological measurement. Its meaning depends on whether 5-((2-aminoethyl)amino)naphthalene-1-sulfonic acid reports molecular proximity in a FRET assay, the environment of a labeled protein, or localized reporter deposition in a TSA-based assay.
What Aβ42 Selectivity Reveals
2026-11-17
A selective reduction in Aβ42, with Aβ40 unchanged, is more informative than a simple claim of global γ-secretase inhibition. It suggests species-dependent effects in a human neuroglioma-cell model, while leaving the precise molecular basis and broader biological relevance unresolved.
How Hydroxychloroquine Links TLR Signaling and Autophagy
2026-11-17
Hydroxychloroquine Sulfate is documented as a modulator of autophagy and TLR7/9 signaling. This article explains how those mechanisms relate to immune readouts, why pathway markers and cell-growth outcomes are not interchangeable, and what the reported autoimmune and renal-carcinoma contexts can—and cannot—establish.
Why Mutant-Selective EGFR Inhibition Needs Context
2026-11-16
EAI045 is documented as an allosteric inhibitor that preferentially targets selected drug-resistant EGFR mutants. Its reported biochemical potency does not translate directly into tumor regression: cellular signaling state, receptor context and antibody combination all affect the observed outcome.
What 5-EdU Can—and Cannot—Show in SCI
2026-11-16
A source-grounded interpretation of 5-EdU as a DNA-synthesis readout in spinal cord injury research, separating cell-cycle measurement from evidence for glial mechanism, tissue repair, and functional recovery.
When Context Changes a Histology Result
2026-11-15
Hematoxylin can provide nuclear and tissue contrast, but the biological meaning of a histological result depends on the model, comparator, developmental stage, proxy exposure, and independent readouts. A neonatal pig study illustrates how morphology, FOXA2 localization, and transcriptomics can support an association without proving a single causal mechanism.
What Does Oleoylcarnitine Signal in Liver Metabolism?
2026-11-14
Oleoylcarnitine is best interpreted as a metabolic signal of disrupted long-chain fatty-acid handling, particularly when fatty acid β-oxidation is impaired. Its proposed connection to hepatocellular carcinogenesis is hypothesis-generating rather than proof that the metabolite independently causes liver cancer.
How Receptor Actions Shape GI Readouts
2026-11-13
A receptor-to-physiology framework for interpreting metoclopramide’s documented mechanism, gastrointestinal contexts, and the limits of product-level evidence.
What Shikimic Acid Cell Evidence Means
2026-11-13
Shikimic acid has a defined role as a shikimate pathway intermediate and a separate, model-specific association with reduced oxidative-stress readouts in SH-SY5Y cells. Together, these facts support a focused cellular antioxidant observation, but they do not establish a direct molecular mechanism or organism-level neuroprotection.